iiinova — where your digital self keeps evolving

John Ebos

@ebos.bsky.social

1.4K followers 1.8K following 89 posts

Associate Prof. in Cancer Genetics at Roswell Park Comprehensive Cancer Center studying drug resistance, metastasis, the tumor microenvironment, immunecheckpoints, and angiogenesis. www.roswellpark.org/research/labs/e…

Posts Replies Media

John Ebos @ebos.bsky.social · 01/06/2026

Thank you to all the organizers at the American Cancer Society Relay for Life event this weekend in Niagara Falls for all of their hard work on behalf of patients to help fund critical cancer research! @americancancersoc.bsky.social @roswellpark.bsky.social secure.acsevents.org/site/STR?pg=...

040

John Ebos @ebos.bsky.social · 22/01/2026

Thank you to the American Cancer Society for highlighting our lab, this means a great deal. Please join the Making Strides Against Breast Cancer Fundraiser October 17, 2026 www.facebook.com/groups/makin...

010

John Ebos @ebos.bsky.social · 22/08/2025

here is our detailed schematic!

140

John Ebos @ebos.bsky.social · 07/03/2025

Stand up for science buffalo!

0121

John Ebos @ebos.bsky.social · 21/02/2025

Excellent presentations yesterday at the Translational Research Cancer Centers Consortium annual meeting. Congratulations to everyone for excellent talks! #TRCCC25

020

John Ebos @ebos.bsky.social · 11/12/2024

This work also could not have happened without Amber McKenery in the Ebos Lab, who drove this project in the final years. Thank you, Amber!

110

John Ebos @ebos.bsky.social · 11/12/2024

This work was the result of years of dedicated work and sacrifice by Yuhao (Tom) Shi, a talented MD/PhD @ubuffalo.bsky.social student in the Ebos Lab who received F30 NIH Funding from the NCI and is now doing his residency in NYU's #radonc program. Congratulations Tom!

111

John Ebos @ebos.bsky.social · 11/12/2024

We found that the interferon-regulated secretory machinery in tumor cells is ‘rewired’ after acquired resistance to PD-L1 inhibition, altering the immune microenvironment and decreasing the tumor-killing ability of T cells. @roswellpark.bsky.social #oncosky #medsky #cancerresearch #drugresistance

162

John Ebos @ebos.bsky.social · 14/11/2024

Able to capture the esteemed @mikefeigin.bsky.social and Ethan Abel discussing their next big discovery

120

John Ebos @ebos.bsky.social · 14/11/2024

Excellent retreat today showcasing all of the amazing science a Roswell Park Comprehensive Cancer Center.

141

John Ebos @ebos.bsky.social · 01/05/2024

Our study identifies an unexpected 'senomimetic' side-effect of TKIs more typically associated with blocking angiogenesis. VEGFR TKIs can modulate nearby immune cell activity by promoting IFN/STING signaling, which improves response with PD-L1 inhibitors.

000

John Ebos @ebos.bsky.social · 25/11/2023

Multiomics of HER2-low triple-negative breast cancer identifies a receptor tyrosine kinase–relevant subgroup with therapeutic prospects insight.jci.org/articles/6106

011